Rituximab provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in SMZL patients that were either untreated or were splenectomised, but had shown disease progression within 1 year after splenectomy. Treatment consisted of 6 courses of rituximab with cyclophosphamide, vincristine, non-pegilated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-years progression free survival and overall survival was 54% and 72%, respectively. Toxicity was substantial (grade ≥3 neutropenia: 26%; grade ≥3 infections: 8%). Of the 15 deaths, 2 occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, 4 to secondary neoplasia, 1 to sepsis, 1 to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study / Iannitto, Emilio; Luminari, Stefano; Tripodo, Claudio; Mancuso, Salvatrice; Cesaretti, Marina; Marcheselli, Luigi; Merli, Francesco; Stelitano, Caterina; Carella, Angelo Michele; Fragasso, Alberto; Montechiarello, Elisa; Ricciuti, Giuseppina; Pulsoni, Alessandro; Paulli, Marco; Franco, Vito; Federico, Massimo. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 56:12(2015), pp. 3281-3287. [10.3109/10428194.2015.1029925]

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study

LUMINARI, Stefano;CESARETTI, Marina;MARCHESELLI, Luigi;FEDERICO, Massimo
2015

Abstract

Rituximab provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in SMZL patients that were either untreated or were splenectomised, but had shown disease progression within 1 year after splenectomy. Treatment consisted of 6 courses of rituximab with cyclophosphamide, vincristine, non-pegilated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-years progression free survival and overall survival was 54% and 72%, respectively. Toxicity was substantial (grade ≥3 neutropenia: 26%; grade ≥3 infections: 8%). Of the 15 deaths, 2 occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, 4 to secondary neoplasia, 1 to sepsis, 1 to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.
2015
18-lug-2015
56
12
3281
3287
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study / Iannitto, Emilio; Luminari, Stefano; Tripodo, Claudio; Mancuso, Salvatrice; Cesaretti, Marina; Marcheselli, Luigi; Merli, Francesco; Stelitano, Caterina; Carella, Angelo Michele; Fragasso, Alberto; Montechiarello, Elisa; Ricciuti, Giuseppina; Pulsoni, Alessandro; Paulli, Marco; Franco, Vito; Federico, Massimo. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 56:12(2015), pp. 3281-3287. [10.3109/10428194.2015.1029925]
Iannitto, Emilio; Luminari, Stefano; Tripodo, Claudio; Mancuso, Salvatrice; Cesaretti, Marina; Marcheselli, Luigi; Merli, Francesco; Stelitano, Cateri...espandi
File in questo prodotto:
File Dimensione Formato  
410 (ex747).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 556.5 kB
Formato Adobe PDF
556.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1065868
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact